Martin A Katzman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5348301/publications.pdf

Version: 2024-02-01

21 1,382 14 21 g-index

25 25 25 25 2453

times ranked

docs citations

all docs

citing authors

#	Article	IF	CITATIONS
1	Smartphone-Detected Ambient Speech and Self-Reported Measures of Anxiety and Depression: Exploratory Observational Study. JMIR Formative Research, 2021, 5, e22723.	1.4	13
2	Automated Screening for Social Anxiety, Generalized Anxiety, and Depression From Objective Smartphone-Collected Data: Cross-sectional Study. Journal of Medical Internet Research, 2021, 23, e28918.	4.3	20
3	Effects of desvenlafaxine versus placebo on MDD symptom clusters: A pooled analysis. Journal of Psychopharmacology, 2020, 34, 280-292.	4.0	10
4	The Relationship Between Smartphone-Recorded Environmental Audio and Symptomatology of Anxiety and Depression: Exploratory Study. JMIR Formative Research, 2020, 4, e18751.	1.4	29
5	Functional Recovery in Major Depressive Disorder: Providing Early Optimal Treatment for the Individual Patient. International Journal of Neuropsychopharmacology, 2018, 21, 128-144.	2.1	68
6	Patient Willingness to Consent to Mobile Phone Data Collection for Mental Health Apps: Structured Questionnaire. JMIR Mental Health, 2018, 5, e56.	3.3	55
7	Neurobiology of hedonic tone: the relationship between treatment-resistant depression, attention-deficit hyperactivity disorder, and substance abuse. Neuropsychiatric Disease and Treatment, 2016, Volume 12, 2149-2164.	2.2	54
8	Re. Canadian Journal of Psychiatry, 2016, 61, 60-61.	1.9	12
9	Biodiversity, the Human Microbiome and Mental Health: Moving toward a New Clinical Ecology for the 21st Century?. International Journal of Biodiversity, 2016, 2016, 1-18.	0.7	26
10	Examining the role of neuroinflammation in major depression. Psychiatry Research, 2015, 229, 27-36.	3.3	160
11	Natural environments, ancestral diets, and microbial ecology: is there a modern "paleo-deficit disorder� Part II. Journal of Physiological Anthropology, 2015, 34, 9.	2.6	25
12	Neuroinflammatory pathways in anxiety, posttraumatic stress, and obsessive compulsive disorders. Psychiatry Research, 2015, 229, 37-48.	3.3	145
13	Pharmacological approaches to manage persistent symptoms of major depressive disorder: rationale and therapeutic strategies. Psychiatry Research, 2014, 220, S15-S33.	3.3	18
14	Acne as a Potential Adverse Effect of Duloxetine. Journal of Microbiology and Biotechnology, 2014, 24, 408-410.	2.1	1
15	Managing major depressive disorder through the use of adjunct therapies. Psychiatry Research, 2014, 220, S1-S2.	3.3	2
16	Food for thought: understanding the value, variety and usage of management algorithms for major depressive disorder. Psychiatry Research, 2014, 220, S3-S14.	3.3	5
17	A randomized, double-blind, placebo-controlled pilot study of a probiotic in emotional symptoms of chronic fatigue syndrome. Gut Pathogens, 2009, 1, 6.	3.4	448
18	Paroxetine Versus Placebo and Other Agents for Depressive Disorders. Journal of Clinical Psychiatry, 2007, 68, 1845-1859.	2.2	19

#	Article	IF	CITATIONS
19	Major depressive disorder: probiotics may be an adjuvant therapy. Medical Hypotheses, 2005, 64, 533-538.	1.5	225
20	Effects of CCK-tetrapeptide in patients with social phobia and obsessive-compulsive disorder. Depression and Anxiety, 2004, 20, 51-58.	4.1	18
21	Acute and Chronic Role of 5-HT3 Neuronal System on Behavioral and Neuroendocrine Changes Induced by Intravenous Cholecystokinin Tetrapeptide Administration in Humans. Neuropsychopharmacology, 1999, 20, 177-187.	5.4	29